AndhraNews.net
Home » Business News » 2013 » May » May 20, 2013

Atossa Genetics to Present at the Sidoti Semi-Annual Microcap Conference


May 20, 2013 - SEATTLE, WA

Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced that Dr. Steven Quay, chairman, CEO and president, will be presenting at the Sidoti Semi-Annual Microcap Conference on Friday, June 7, 2013, at 2:00 p.m. Eastern Time, at the Grand Hyatt Hotel in New York City. In addition to presenting the company story, management will be available for one-on-one meetings with institutional investors.

For more information about the conference or to schedule a one-on-one meeting with Atossa's management, please contact your Sidoti representative or visit www.sidoti.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS) (www.atossagenetics.com), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH; www.nrlbh.com), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA. The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:

Atossa Genetics, Inc.
Kyle Guse
Chief Financial Officer and General Counsel
800-351-3902
Email Contact

Matthew D. Haines (Investors)
Managing Director
MBS Value Partners
212-710-9686
Email Contact

MarketWire

Comment on this story

Share